The one-year durability data in SPS and gMG de-risk the BLA filing and support miv-cel's potential as first approved CAR T for autoimmune disease. Key catalysts ahead: completion of rolling BLA in Q4 2026, full data presentation at MS Toronto (Oct 21-23), and Phase 3 gMG enrollment completion by mid-2027. Monitor FDA acceptance and priority review status post-BLA submission.
Price Chart
Executive Summary
Kyverna Therapeutics reported positive one-year durability data from its registrational KYSA-8 trial of miv-cel in stiff person syndrome (SPS), showing sustained 49% median improvement in T25FW at month 12 and 92% of patients free of chronic immunotherapies. Longer-term Phase 2 follow-up in generalized myasthenia gravis (gMG) showed all 7 patients maintained clinically meaningful improvements through one year or longer, with 57% maintaining minimal symptom expression. The rolling BLA submission for SPS remains on track for Q4 2026 completion, and Phase 3 enrollment in gMG is expected to complete by mid-2027.
Key Facts
- One-year SPS data: median T25FW improvement of 49% at month 12 (p < 0.0001), sustained from 46% at week 16
- 95% of SPS patients who achieved clinically meaningful improvement at primary analysis sustained benefit through month 12
- 67% of SPS patients requiring walking aid prior to treatment no longer require assistance
- 92% of SPS patients remained free of chronic immunotherapies at 12 months
- No high-grade CRS, ICANS, or IEC-HS in SPS or gMG trials
- gMG Phase 2: all 7 patients achieved clinically meaningful improvement in MG-ADL and QMG at 24 weeks; 57% maintained MSE as of last follow-up
- 86% of gMG patients remained off immunosuppressants as of last follow-up
- Rolling BLA submission for SPS on track for completion in Q4 2026
- Phase 3 gMG trial enrollment expected to complete in mid-2027
- Miv-cel has received three FDA RMAT designations (SPS, gMG, naSPMS)
Financial Impact
No financial data in filing; clinical-stage biotech with no approved products or reported revenue
Risk Factors
- BLA submission and FDA review timelines may be delayed or result in a Complete Response Letter
- Phase 3 gMG trial (randomized vs SOC) may not replicate Phase 2 open-label results
- Competition from other autoimmune CAR T programs and approved therapies (FcRn inhibitors, complement inhibitors)
- Manufacturing scale-up and commercial launch execution risks for autologous CAR T
- Small sample sizes (n=26 SPS, n=7 gMG) limit statistical robustness of longer-term durability claims
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-400062 |
| Document: kytx-20260924.htm | 0001193125-26-400062 |
| Document: 0001193125-26-400062-index-headers.html | 0001193125-26-400062 |
| Document: 0001193125-26-400062-index.html | 0001193125-26-400062 |
| Document: 0001193125-26-400062.txt | 0001193125-26-400062 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | SC 13G | $5.83 $6.04 | ▲ +3.60% | ▲ +3.27% | $5.63 (−3.43%) |
Sep 24, 2026 4w ago | 8-K | $6.99 $6.81 | ▼ −2.58% | ▼ −3.12% | $5.63 (−19.46%) |
Aug 11, 2026 11w ago | 8-K | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.63 (−30.06%) |
Aug 11, 2026 11w ago | Press Release | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.63 (−30.06%) |
Jul 27, 2026 13w ago | 8-K | $7.92 $7.49 | ▼ −5.43% | ▼ −5.67% | $5.63 (−28.91%) |
Jul 9, 2026 15w ago | 8-K | $9.81 $8.49 | ▼ −13.51% | ▼ −13.94% | $5.63 (−42.61%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.06 $8.15 | ▼ −1.18% | ▲ +0.58% | $5.63 (+30.11%) |
May 4, 2026 25w ago | 8-K | $9.00 $9.21 | ▲ +2.33% | ▲ +1.54% | $5.63 (−37.44%) |
Apr 22, 2026 26w ago | 8-K | $10.23 $8.95 | ▼ −12.51% | ▼ −12.12% | $5.63 (−44.97%) |
Apr 20, 2026 27w ago | Press Release | $11.25 $9.71 | ▼ −13.69% | ▼ −13.04% | $5.63 (−49.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers